login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VERA THERAPEUTICS INC (VERA) Stock News
USA
-
Nasdaq
- NASDAQ:VERA -
US92337R1014
-
Common Stock
33.75
USD
+0.42 (+1.26%)
Last: 11/28/2025, 8:05:05 PM
33.75
USD
0 (0%)
After Hours:
11/28/2025, 8:05:05 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VERA Latest News, Press Relases and Analysis
All
Press Releases
5 days ago - By: Chartmill
- Mentions:
URBN
WOOF
HPQ
INV
...
Get insights into the top gainers and losers of Tuesday's after-hours session.
3 days ago - By: The Motley Fool
Why Vera Therapeutics Stock Crushed it Today
4 days ago - By: Vera Therapeutics
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
4 days ago - By: Vera Therapeutics
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
6 days ago - By: Vera Therapeutics
Vera Therapeutics to Participate at Upcoming Investor Conferences
6 days ago - By: Vera Therapeutics
Vera Therapeutics to Participate at Upcoming Investor Conferences
20 days ago - By: Vera Therapeutics
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
20 days ago - By: Vera Therapeutics
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
23 days ago - By: Vera Therapeutics
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
23 days ago - By: Vera Therapeutics
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
23 days ago - By: Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 days ago - By: Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 days ago - By: Vera Therapeutics
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
24 days ago - By: Vera Therapeutics
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
25 days ago - By: Benzinga
- Mentions:
AMGN
GILD
TEVA
PFE
...
10 Health Care Stocks Whale Activity In Today's Session
25 days ago - By: Vera Therapeutics
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
25 days ago - By: Vera Therapeutics
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
a month ago - By: Vera Therapeutics
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
a month ago - By: Vera Therapeutics
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
a month ago - By: Vera Therapeutics
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
a month ago - By: Vera Therapeutics
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
a month ago - By: Benzinga
- Mentions:
VRTX
BAC
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market
2 months ago - By: Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Vera Therapeutics
Vera Therapeutics to Participate at Upcoming Investor Conferences
3 months ago - By: Vera Therapeutics
Vera Therapeutics to Participate at Upcoming Investor Conferences
4 months ago - By: Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: The Motley Fool
Vera (VERA) Q2 Net Loss Widens 127%
4 months ago - By: Vera Therapeutics
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
4 months ago - By: Vera Therapeutics
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Please enable JavaScript to continue using this application.